MedPath

Concordance and Acceptability of Self-screening Versus Screening by a Healthcare Professional for HPV, a Risk Factor for Anal Cancer, by Swab in People Living With HIV

Not Applicable
Not yet recruiting
Conditions
HPV Infection
Interventions
Diagnostic Test: anal swabbing
Registration Number
NCT06507917
Lead Sponsor
Centre Hospitalier Universitaire de la Réunion
Brief Summary

Anal canal cancers are on the increase in France, with around 2,000 new cases per year. These lesions can be detected by directed biopsies or smear tests.

The incidence rate of anal cancer is 30 times higher in people living with HIV than in the general population.

According to a recent study, the risk of anal cancer is highest in this population, but is also high in heterosexual men over 30 and women over 30. However, the proposal of a proctological examination in this population is not systematic.

In France, there is no HPV screening for people living with HIV, but there is a recommendation for proctology consultation in certain cases, notably for men who have sex with men (MSM) or for women with vaginal cervical lesions.

Several oncogenic HPV serotypes have been identified in the genesis of anal cancer. The serotype identified as the most carcinogenic is HPV-16 (89%).

This study will look at anal HPV screening in people over 30 living with HIV, thus including a population for which no screening is currently offered (heterosexual men living with HIV and women living with HIV without vaginal cervical lesions), and will assess the concordance and acceptability of self-screening versus screening by a healthcare professional as part of a comprehensive anal cancer screening strategy in this population.

Detailed Description

Not available

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
398
Inclusion Criteria

Patient :

  • living with HIV
  • aged 30 or over
  • resident on Reunion island and followed at the University Hospital of Reunion Island (the only follow-up center on the island)
  • Able to perform anal self-sampling
  • Able to answer a questionnaire
  • Affiliated with or benefiting from a social security scheme
  • Have given free, informed and signed consent
Exclusion Criteria
  • People with a previous anal swab less than 7 days old
  • Persons with a known current diagnosis of anal cancer
  • Persons deprived of liberty by judicial or administrative decision, minors, and persons under legal protection: guardianship or curators

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
self-swabbing firstanal swabbingGroup A self-swabbing then swabbing by a healthcare professional
swabbing by a healthcare professional firstanal swabbingswabbing by a healthcare professional and then self-swabbing
Primary Outcome Measures
NameTimeMethod
Evaluate the concordance of HPV-16 genotype results between self-sampling and professional sampling.7 days

HPV-16 genotype results for the sample

Secondary Outcome Measures
NameTimeMethod
Evaluate the concordance of results for other oncogenic HPV genotypes between self-sampling and professional sampling.7 days

HPV oncogenic genotype results for the sample

Compare the proportion of adverse events (discomfort, pain, bleeding, itching) in the 2 groups.7 days

discomfort, pain, bleeding, inconvenience after each swabbing

Evaluate the prevalence of anal HPV (including oncogenic HPV).7 days

The proportion and prevalence of the various HPVs in the study population will be described.

To assess the preference of anal self-swabbing over anal swabbing performed by a healthcare professional.7 days

visual scale from 0 (strongly disagree) to 10 (strongly agree)

Compare the overall satisfaction of the 2 anal samplings.7 days

visual scale from 0 (poor) to 10 (very good).

Compare the acceptability of anal self-swabbing versus anal swabbing performed by a healthcare professional.7 days

composite score, constructed from the satisfaction scores, from which we subtract the average of the adverse event and shame scores, asked after each swab.

Trial Locations

Locations (1)

CHU de la Réunion Recherche Clinique

🇷🇪

Saint-Pierre, Réunion

© Copyright 2025. All Rights Reserved by MedPath